莫沙必利与奥美拉唑镁联合用药在治疗反流性食管炎中的临床效果及安全性评估

Clinical Efficacy and Safety Assessment of the Combination of Mosapride and Omeprazole Magnesium in the Treatment of Reflux Esophagitis

目的 评估莫沙必利联合奥美拉唑镁在治疗反流性食管炎中的疗效与安全性。方法 回顾性选取2022年6月—2024年1月汀州医院消化内科收治的300例反流性食管炎患者的临床资料,根据治疗方法不同分为两组,每组150例。常规组应用奥美拉唑镁治疗,联合组应用奥美拉唑镁联合莫沙必利治疗。对比两组胃功能指标、炎性因子指标水平、不适症状积分、不良反应发生率。结果 治疗后,联合组胃蛋白酶原Ⅰ、胃蛋白酶原Ⅱ、胃泌素17水平均优于常规组,差异有统计学意义(P均<0.05)。联合组白细胞介素(interleukin, IL)-4、IL-7、IL-17水平均低于常规组,差异有统计学意义(P均<0.05)。联合组烧心、反酸、嗳气积分均低于常规组,差异有统计学意义(P均<0.05)。联合组不良反应发生率为8.00%(12/150),高于常规组的4.00%(6/150),差异无统计学意义(χ^(2)=2.128,P>0.05)。结论 莫沙必联合奥美拉唑镁在治疗反流性食管炎中的疗效较高,能有效改善患者的胃功能,减少炎性因子水平,同时并未增加不良反应发生率,安全性较高。

Objective To evaluate the efficacy and safety of mosapride combined with omeprazole magnesium in the treatment of reflux esophagitis.Methods The clinical data of 300 patients with reflux esophagitis admitted to the Department of Gastroenterology of Tingzhou Hospital from June 2022 to January 2024 were retrospectively selected.According to different treatment methods,they were divided into two groups,150 cases in each group.The conventional group was treated with omeprazole magnesium,and the combined group was treated with omeprazole magnesium combined with mosapride.The gastric function index,inflammatory factor index level,discomfort symptom score and incidence of adverse reactions were compared between the two groups.Results After treatment,the levels of pepsinogenⅠ,pepsinogenⅡand gastrin 17 in the combined group were better than those in the conventional group,and the differences were statistically significant(all P<0.05).The levels of interleukin(IL)-4,IL-7 and IL-17 in the combined group were lower than those in the conventional group,and the differences were statistically significant(all P<0.05).The scores of heartburn,acid reflux and belching in the combined group were lower than those in the conventional group,and the differences were statistically significant(all P<0.05).The incidence of adverse reactions in the combined group was 8.00%(12/150),which was higher than 4.00%(6/150)in the conventional group,and the difference was not statistically significant(χ^(2)=2.128,P>0.05).Conclusion Mosapride combined with omeprazole magnesium is effective in the treatment of reflux esophagitis.Which can effectively improve the gastric function of patients and reduce the level of inflammatory factors.At the same time,it does not increase the incidence of adverse reactions and has high safety.